Atto Billio

Publications (3)9.64 Total impact

• Article: SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.

  Pier Luigi Zinzani, Monia Marchetti, Atto Billio, Giovanni Barosi, Angelo Michele Carella, Mario Lazzarino, Maurizio Martelli, Alessandro Rambaldi, Luigi Rigacci, Corrado Tarella, Umberto Vitolo, Sante Tura
  [show abstract] [hide abstract]
  ABSTRACT: By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage III-IV disease and/or high tumor burden. Maintenance rituximab was also recommended in responding patients. In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross-resistant regimens followed by rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy.
  American Journal of Hematology 12/2012; · 4.67 Impact Factor
• Article: SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.

  Giovanni Barosi, Giampaolo Merlini, Atto Billio, Mario Boccadoro, Paolo Corradini, Monia Marchetti, Massimo Massaia, Patrizia Tosi, Antonio Palumbo, Michele Cavo, Sante Tura
  [show abstract] [hide abstract]
  ABSTRACT: In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recommendations. We recommended thalidomide and bortezomib in MM patients candidates to autologous stem cell transplantation (ASCT) (weak positive). We did not recommend novel agents as maintenance therapy after ASCT (weak negative). In patients not candidate to ASCT, thalidomide or bortezomib (strong positive) associated with melphalan and prednisone were recommended. In these patients, no specific course of action could be recommended as for maintenance therapy. In patients who are refractory or relapsing after first-line therapy, we recommended bortezomib and pegylated liposomal doxorubicin, or lenalidomide and dexamethasone combinations (weak positive).
  Annals of Hematology 04/2012; 91(6):875-88. · 2.62 Impact Factor
• Source

  Available from: Giovanna Meloni

  Article: SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia.

  Francesca Romana Mauro, Giuseppe Bandini, Giovanni Barosi, Atto Billio, Maura Brugiatelli, Antonio Cuneo, Francesco Lauria, Vincenzo Liso, Monia Marchetti, Giovanna Meloni, Marco Montillo, Pierluigi Zinzani, Sante Tura
  [show abstract] [hide abstract]
  ABSTRACT: By using GRADE system we updated the guidelines for management of CLL issued in 2006 from SIE, SIES and GITMO group. We recommended fludarabine, cyclophosphamide, rituximab (FCR) in younger and selected older patients with a good fitness status, no unfavourable genetics (deletion 17p and/or p53 mutations), and a less toxic treatment in nonfit and elderly patients. In patients without unfavourable genetics, relapsed after 24 months the same initial treatment including rituximab can be considered. In patients with unfavourable genetics, refractory or relapsed within 24 months from a prior fludarabine-based treatment, allogeneic SCT or experimental treatments should be given.
  Leukemia research 08/2011; 36(4):459-66. · 2.36 Impact Factor